Contents 3 min read

Claim and source comparison

Comparison scope: Grant 2009, Bloch 2013, Sarris 2022 and LaRowe 2007 abstracts; Acepiro oral-label safety/pharmacokinetic sections and FDA 2022 guidance summary. Not a complete clinical or independent medical review.

· Bounded source comparison; not a complete clinical review or independent medical endorsement.

Human controlled trial; randomization not verified

Grant 2009: In 50 adults with trichotillomania, NAC 1200–2400 mg/day for 12 weeks reduced hair-pulling symptoms more than placebo. Much/very much improved rates were 56% and 16%.

The accessed abstract does not explicitly report randomization. This small adult trial cannot be generalized to children, all impulse disorders or healthy cognition; its dose is not a personal prescription.

Source 2 · Abstract read

Human randomized controlled trial

Bloch 2013: In 39 children/adolescents aged 8–17, randomized 12-week add-on NAC did not significantly differ from placebo on primary or secondary hair-pulling outcomes. Response rates were 25% and 21%.

Positive adult findings do not establish pediatric efficacy. Improvement over time in both groups is not a NAC effect; this trial defines neither personal pediatric dosing nor a general safety limit.

Source 8 · Abstract read

Human randomized controlled trial

Sarris 2022: 98 people with OCD were randomized; 89 with at least one follow-up visit were analyzed. Add-on NAC 2–4 g/day for twenty weeks was not superior to placebo: difference 0.53 (95% interval −2.18–3.23; p=0.70).

Randomized and analyzed populations differ. Doses were adjusted by response; the research range is not a personal titration protocol or replacement for standard psychiatric care.

Source 5 · Abstract read

Human controlled trial; randomization not verified

LaRowe 2007: In 15 cocaine-dependent participants, a double-blind crossover comparison with two three-day hospital stays found less desire/interest and viewing time for cocaine images during NAC.

The abstract does not explicitly verify randomization. Laboratory cue reactivity is not real-world abstinence, relapse prevention or treatment of every addiction.

Source 3 · Abstract read

Official safety summary

The Acepiro oral label reports about two hours plasma half-life after 600 mg and, separately, about six hours mean terminal half-life. Parent compound, metabolites and protein-bound forms are not the same measurement.

No new universal curve replaces the unscoped 5.6 hours. Phase, assay, product and liver status matter; these data do not establish personal redosing or duration of brain effects.

Source 9 · Official summary read

Official safety summary

The Acepiro label notes that NAC may enhance nitroglycerin vasodilation and requires monitoring for hypotension. The clinical significance of reduced platelet aggregation is unestablished. Breathing difficulty, hypersensitivity and digestive symptoms are among product cautions.

A specific oral drug's cautions do not establish equal side-effect rates for every supplement or proven bleeding increases with every anticoagulant. Do not independently stop medication; missing interaction records do not establish safety.

Source 9 · Official summary read

Regulatory scientific assessment

FDA's August 2022 guidance describes enforcement discretion for certain NAC products meeting specified conditions. This does not mean every NAC product is drug-approved or has identical status in all countries.

The official summary describes policy scope; it is not personal-use permission, a current country/product authorization check or clinical efficacy assessment.

Source 7 · Official summary read

Our evidence and source methodology

NAC: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans.

What is NAC?

NAC is involved in cysteine and glutathione metabolism. It has a medical use in acetaminophen poisoning; it is not an equally established general treatment for neuroprotection, OCD or addiction.

Clinical Trials

Grant 2009: In 50 adults with trichotillomania, NAC 1200–2400 mg/day for 12 weeks reduced hair-pulling symptoms more than placebo. Much/very much improved rates were 56% and 16%.

The accessed abstract does not explicitly report randomization. This small adult trial cannot be generalized to children, all impulse disorders or healthy cognition; its dose is not a personal prescription.

Bloch 2013: In 39 children/adolescents aged 8–17, randomized 12-week add-on NAC did not significantly differ from placebo on primary or secondary hair-pulling outcomes. Response rates were 25% and 21%.

Positive adult findings do not establish pediatric efficacy. Improvement over time in both groups is not a NAC effect; this trial defines neither personal pediatric dosing nor a general safety limit.

Sarris 2022: 98 people with OCD were randomized; 89 with at least one follow-up visit were analyzed. Add-on NAC 2–4 g/day for twenty weeks was not superior to placebo: difference 0.53 (95% interval −2.18–3.23; p=0.70).

Randomized and analyzed populations differ. Doses were adjusted by response; the research range is not a personal titration protocol or replacement for standard psychiatric care.

LaRowe 2007: In 15 cocaine-dependent participants, a double-blind crossover comparison with two three-day hospital stays found less desire/interest and viewing time for cocaine images during NAC.

The abstract does not explicitly verify randomization. Laboratory cue reactivity is not real-world abstinence, relapse prevention or treatment of every addiction.

Dose information and research limits

Dose information and research limits

This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

The Acepiro oral label reports about two hours plasma half-life after 600 mg and, separately, about six hours mean terminal half-life. Parent compound, metabolites and protein-bound forms are not the same measurement.

No new universal curve replaces the unscoped 5.6 hours. Phase, assay, product and liver status matter; these data do not establish personal redosing or duration of brain effects.

Safety and Side Effects

The Acepiro label notes that NAC may enhance nitroglycerin vasodilation and requires monitoring for hypotension. The clinical significance of reduced platelet aggregation is unestablished. Breathing difficulty, hypersensitivity and digestive symptoms are among product cautions.

A specific oral drug's cautions do not establish equal side-effect rates for every supplement or proven bleeding increases with every anticoagulant. Do not independently stop medication; missing interaction records do not establish safety.

FDA's August 2022 guidance describes enforcement discretion for certain NAC products meeting specified conditions. This does not mean every NAC product is drug-approved or has identical status in all countries.

The official summary describes policy scope; it is not personal-use permission, a current country/product authorization check or clinical efficacy assessment.

Related research and reading

These links show explicit editorial topic connections; they do not confirm a mechanism, efficacy or the safety of combined use. News dates refer to the source or event.

Educational guides

Sources

  1. Berk M, et al. (2008). N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial. Biological Psychiatry, 64(5), 361–368. PubMed · PMID 18436195
  2. Grant JE, et al. (2009). N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry, 66(7), 756–763. PubMed · PMID 19581567
  3. LaRowe SD, et al. (2007). Is cocaine desire reduced by N-acetylcysteine? American Journal of Psychiatry, 164(7), 1115–1117. PubMed · PMID 17606664
  4. Dean O, et al. (2011). N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. Journal of Psychiatry & Neuroscience, 36(2), 78–86. PubMed · PMID 21118657
  5. Sarris J, et al. (2022). N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 117, 110550. https://doi.org/10.1016/j.pnpbp.2022.110550 PubMed · PMID 35304155
  6. Richie JP Jr, et al. (2015). Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. European Journal of Nutrition, 54(2), 251–63. https://doi.org/10.1007/s00394-014-0706-z PubMed · PMID 24791752
  7. US Food and Drug Administration. Guidance for Industry: Policy Regarding N-acetyl-L-cysteine. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-policy-regarding-n-acetyl-l-cysteine US Food and Drug Administration
  8. Bloch MH, et al. (2013). N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child and Adolescent Psychiatry, 52(3), 231-40. https://doi.org/10.1016/j.jaac.2012.12.020 PubMed · PMID 23452680
  9. Stirling Anglian Pharmaceuticals. Acepiro 600 mg effervescent tablets: Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/13849/smpc Stirling Anglian Pharmaceuticals / electronic medicines compendium

Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory

Frequently Asked Questions